What is DexCom's stock symbol?
DexCom trades on the NASDAQ under the ticker symbol "DXCM."
Where is DexCom's stock going? Where will DexCom's stock price be in 2017?
16 analysts have issued 12-month price targets for DexCom's stock. Their forecasts range from $66.00 to $112.00. On average, they anticipate DexCom's share price to reach $92.27 in the next twelve months.
When will DexCom announce their earnings?
DexCom is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
What are analysts saying about DexCom stock?
Here are some recent quotes from research analysts about DexCom stock:
According to Zacks Investment Research, "In the past six months, DexCom has outperformed the broader industry sentiments with respect to price performance. However, a disappointing estimate revision trend indicates looming concerns ahead. DexCom reported wider than expected third quarter loss. We believe the company’s margins would continue to be under pressure in the coming quarters owing to high product development costs and rising expenditures on research & development along with marketing. Specifically, the company is expected to lose a few margins on transmitter sales in spite of the cost reduction initiatives (which are expected to be effective only by the second half of 2017). Additionally, cutthroat competition in the market for blood glucose monitoring devices is a headwind. Nevertheless, the reimbursement approval in Germany is a key catalyst in our view. The proposed non-adjunctive indication for DexCom’s G5 Mobile CGM system ia also a significant positive." (1/9/2017)
BTIG Research analysts commented, "Most Important; But The Report Was Not Clean; Buy As we previewed, revenue of $137.3M was in-line with our estimate and well above the street. We think this is most important. GMs disappointed and the $10M guidance raise was likely less than some hoped. With the stock having run from the $60s to the $90s, it is not surprising to see it pull back to the mid $80s afterhours. We would opportunistically buy shares on dips and would become aggressive around $80. Top-line growth continues to beat expectations, thesis remains the same though in the $80s, upside has moderated. Having crushed both Q1 and Q2 sales expectations, we see DXCM as meeting our growth thesis. We believe some expected a raise beyond the new $550-$575M FY16 guidance. While this may pressure shares tomorrow we note during Q&A, mgmt did discuss how they would be pleased to come in above this when asked about $575-$600M. We model above guidance with $581M for Fy16." (8/4/2016)
Canaccord Genuity analysts commented, "We reiterate our BUY rating on DexCom following another exceptional quarter in Q1/16. Revenue growth outpaced guidance and CG/Street estimates. DexCom continues to grow revenues (+60% Y/Y) against extremely difficult comps (+56% in the Q1/15)." (4/28/2016)
Who owns DexCom stock?
DexCom's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (10.67%), Artisan Partners Limited Partnership (8.06%), Baillie Gifford & Co. (7.25%), Brown Advisory Incorporated ("BA Inc") (5.90%), Brown Advisory Inc. (5.68%) and Janus Capital Management LLC (4.22%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Jay S Skyler, Jeffrey Moy, Jess Roper, John Lister, Jonathan T Md Lord, Jorge A Valdes, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg.
Who sold DexCom stock? Who is selling DexCom stock?
DexCom's stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Franklin Resources Inc., FMR LLC, Frontier Capital Management Co. LLC, Fiera Capital Corp, Oberweis Asset Management Inc., Ithaka Group LLC and Gabelli Funds LLC. Company insiders that have sold DexCom stock in the last year include Andrew K Balo, Barbara Kahn, Jay S Skyler, Jeffrey Moy, Jess Roper, John Lister, Jonathan T Md Lord, Jorge A Valdes, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven Robert Pacelli and Terrance H Gregg.
Who bought DexCom stock? Who is buying DexCom stock?
DexCom's stock was bought by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Brown Advisory Inc., Fred Alger Management Inc., State Street Corp, Artisan Partners Limited Partnership, Arrowpoint Asset Management LLC, Paulson & CO. Inc. and Allianz Asset Management AG.
How do I buy DexCom stock?
Shares of DexCom can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of DexCom stock cost?
One share of DexCom stock can currently be purchased for approximately $78.50.